Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock increased by 28.63% to $5.66 during Monday's after-market session. The market value of their outstanding shares is at $47.1 million.
Nektar Therapeutics US Patent & Trademark Office Abstract Showing Patent Grant For Co.’s ‘Method of making a water-soluble polymer-factor VIII moiety conjugate’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6306&f=G&l=50&d=PTXT&p=127&S1=20211012&OS=20211012&RS=20211012
Nektar Therapeutics Reports New Clinical Collab With Merck In Germany, Pfizer To Combine NKTR-255 With Avelumab In JAVELIN Bladder Medley Study
Nektar Therapeutics (NASDAQ:NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's
B of A Securities Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $18
B of A Securities analyst Greg Harrison initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $18.
How Bad Are Nektar Therapeutics’s Earnings? | Return on Capital Employed
Benzinga Pro data, Nektar Therapeutics (NASDAQ:NKTR) reported Q2 sales of $28.33 million. Earnings fell to a loss of $110.20 million, resulting in a 0.74% decrease from last quarter.
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.